Perakakis et al. compared the effects of liraglutide and elafibranor on hepatic parameters in a dietary NAFLD mouse model and suggested that both elafibranor and liraglutide reduced body weight and improved insulin sensitivity and NAS. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.